Clinical trials: Blood Platelet Disease
Acute Coronary Syndrome
Platelets Count Alterations in Patients With Acute Coronary Syndrome
Platelet count alterations (thrombocytopenia and thrombocytosis) are a common condition in patients hospitalised for acute coronary syndrome (ACS), both at disease onset and in the following recovery phase.1-3 Different factors…
- Trial name
- NCT03583411
- Testing
- Epidemiological data collection
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Niguarda Hospital
Thrombocytopenia, Primary Thrombocytopenia,Unspecified
Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia
The increasing need for blood components and the increasingly careful donor selection procedures, make the availability of blood components very reduced, in particular for platelets that are currently administered preferably…
- Conditions
- Thrombocytopenia, Primary Thrombocytopenia,Unspecified, Thrombocytopenia Chemotherapy Induced
- Trial name
- MICE (NCT02032134)
- Testing
- Transfusion of Pooled Platelets Cryopreserved In DMSO
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Napolitano Mariasanta
Acne Vulgaris
Fractional CO2 Laser Delivery of Topical Insulin Versus Platelet Rich Plasma in Treatment of Atrophic Post Acne Scars
compare the efficacy and safety of treating atrophic post acne scars with topical insulin versus Platelet rich Plasma PRP combined with fractional ablative Co2 laser
- Trial name
- NCT06590909
- Testing
- Fractional CO2 laser assisted PDT
- Volunteers
- 22 people
- Sponsor
- Assiut University
Anemia, Hemolytic, Autoimmune, Felty Syndrome
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
OBJECTIVES: I. Determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.
- Conditions
- Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic, Autoimmune Diseases
- Trial name
- NCT00010387
- Testing
- cyclophosphamide, filgrastim
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Johns Hopkins University
Idiopathic Thrombocytopenic Purpura (ITP)
Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.
36 healthy adult men and women will be enrolled with the goal of having 24 subjects complete the entire study. The study will consist of a pre-treatment phase and a treatment phase.
- Trial name
- NCT01437384
- Testing
- E5501
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Atrial Fibrillation
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents
Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown their excellent safety and efficacy…
- Trial name
- NCT04250116
- Testing
- NOAC monotherapy, Dual antithrombotic therapy with NOAC and clopidogrel
- Where
- South Korea
- Volunteers
- 960 people
- Sponsor
- Yonsei University
Gingival Overgrowth, Gingival Hyperplasia
Effect of Injectable Platelet-rich Fibrin (i-PRF) on Wound Healing After Gingivectomy
This study evaluates the clinical and biochemical effects of injectable platelet-rich fibrin (i-PRF) on wound healing after gingivectomy, a surgical procedure used to treat gingival overgrowth.
- Trial name
- i-PRF-GIN (NCT07785349)
- Testing
- injectable Platelet-Rich Fibrin (i-PRF), Conventional Gingivectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Şeyma Çardakçı
Diabetes Mellitus
A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response
The overall objective of this study is to assess P2Y12 inhibition ex vivo in blood samples obtained from diabetic subjects who will be administered one of the two P2Y12 antagonists in a cross-over design.
- Trial name
- NCT03027934
- Testing
- Ticagrelor, Prasugrel
- Sponsor
- CirQuest Labs, LLC
Myelofibrosis, Polycythemia Vera
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia…
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocytosis
- Trial name
- NCT00509899
- Testing
- Ruxolitinib
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Incyte Corporation
Thrombopenia
Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the " Real-life " : Result of the French Experience in 72 Adults
The purpose of this study is to review the charts of the first 100 patients included in the french compassionate program including patients with Immune Thrombopenia receiving romiplostim.
- Trial name
- ATU-r (NCT01013181)
- Volunteers
- 100 people
- Sponsor
- Henri Mondor University Hospital
Diabetic Foot Ulcer, Diabetes Mellitus
Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers
The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both supplemented with platelet rich plasma (PRP) to treat…
- Conditions
- Diabetic Foot Ulcer, Diabetes Mellitus, Diabetic Foot, Diabetic Foot Infection
- Trial name
- NCT05610865
- Testing
- Control; Standard-of-care management, Only PRP injection, PRP + SVF injection
- Where
- Pakistan
- Volunteers
- 28 people
- Sponsor
- University of the Punjab
Von Willebrand Disease (vWD)
An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD). The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa…
- Trial name
- NCT07404644
- Testing
- vonicog alfa (rVWF)
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Takeda
Maternal-Fetal Exchange
Maternal High Blood Pressure and Newborn's Blood Profile
Maternal high blood pressure remodels the intrauterine environment of the fetus by altering hormonal and cellular signaling patterns and, as a result increases the risk of fetal and neonatal mortality and morbidity.
- Trial name
- MPIHHPN (NCT03265704)
- Testing
- AGA - Control group, SGA - Control group, AGA-PIH Study group
- Where
- Romania
- Volunteers
- 6,108 people
- Sponsor
- Romanian Society of Anesthesia and Intensive Care
Periodontitis
Advanced Platelet-Rich Fibrin Plus in Nonsurgical Periodontal Therapy
The purpose of this randomized, controlled, split-mouth clinical trial was to determine whether adding advanced platelet-rich fibrin plus (A-PRF+), an autologous fibrin membrane prepared from the participant's own blood, to…
- Trial name
- NCT07782736
- Testing
- Scaling and Root Planing, Advanced Platelet-Rich Fibrin Plus
- Where
- Vietnam
- Volunteers
- 14 people
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
PreDiabetes
Mechanisms for Activation of Beige Adipose Tissue in Humans
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
- Trial name
- NCT04666636
- Testing
- Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Philip Kern
Myocardial Infarction
Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism
Percutaneous coronary intervention (PCI) with stent implantation is the preferred reperfusion strategy for treatment of acute myocardial infarction (AMI).
- Trial name
- ACCELAMI2C19 (NCT00915733)
- Testing
- cilostazol, clopidogrel (Plavix), CYP2C19
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Gyeongsang National University Hospital
Osteoarthritis, Knee
Mesenchymal Stem Cells Enhanced With PRP Versus PRP In OA Knee
Osteoarthritis (OA) is one of the most common joint diseases.This disease commonly develops in the weight bearing joints of the lower limbs, such as the knee and hip joints.
- Trial name
- MSCPRPOAK (NCT01985633)
- Testing
- Mesenchymal stem cell suspension, PRP
- Where
- India
- Volunteers
- 24 people
- Sponsor
- Aditya K Aggarwal
Hematemesis, Melena
Point of Care Testing of Platelet Function in Patients With Acute Upper Gastrointestinal Bleeding
Acute upper gastrointestinal bleeding (AUGIB) is a common medical emergency. In an ageing population, antiplatelet drugs are increasingly being prescribed for treatment and prophylaxis against cardiovascular thrombo-embolic…
- Conditions
- Hematemesis, Melena, Gastrointestinal Hemorrhage, Platelet Dysfunction
- Trial name
- POCGIB (NCT03028064)
- Testing
- blood taking
- Where
- China
- Volunteers
- 476 people
- Sponsor
- Chinese University of Hong Kong
Hypertensive Emergency-associated Hemolytic Uremic Syndrome
Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
Hemolytic and uremic syndrome (HUS) is a clinic-biological syndrome related to thrombotic microangiopathy affecting predominantly the kidney.
- Trial name
- HYPERSHU (NCT05726916)
- Testing
- Soliris®, Renin angiotensin system blockers
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Scleroderma, Systemic Sclerosis
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies.
- Trial name
- PSSIT (NCT05098704)
- Testing
- clopidogrel treatment
- Where
- 11 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.